The market likes the expansion news, but the company has no money and is deep in debt. They have to raise money. The question is what will be the offering price and how much they are going to dilute. Hence the upward movement has no conviction. Correct me if I am wrong.
such insane volume and yet The Street has offered no opinion, as they usually do, with a sell rating for any company that has been losing money quarter after quarter. Hummm, interesting. Or they already know...
Let this sink in your head!!! fxcm is not for sale. Many people want to buy? Yes!!!!! What happened on Jan/16 was a one day event. That 75 cent valuation was based on that and then. But we should not forget that was just a one day event. fxcm will recover, because it is a viable business. Anyone ever wonder why fxcm would want to forgive negative balances. The reason is they don't want to drive away their traders, who are the life line of their business. In a year or two, the share price will go back up where it was before the crash. You will be glad if you bought today. Remember what happened to the bank stocks in 2008? I am sure glad I bought then. my humble opinion.
It has to accept the reality and make a deal with pip. 30k interest a day? Are they insane? Cut a deal for your own sake!!! A fair deal would be, in my opinion, half net profit up to now after cost, and then half on all future cost and profits US and worldwide. Or Merge as it should have years ago. 195 million sounds absurd indeed, but the judge has no choice but to rule this way as he warned siga at the beginning of the trial. siga thought they could get out of a signed contract for a few millions. Well, they obviously were wrong, and now in denial.
Will the judge rule? Not likely. If he wants to rule, he would have ruled already. The only thing that keeps him from doing that is the possibility of a settlement, but obviously neither party is willing to accept unfavorable terms to them. Anything less than 100 million is unacceptable to pip. Anything over 100 mill is not acceptable to siga. So the only way to open this dead lock is for a third party to buy both companies. Will it be acceptable if someone offers 5 dollars a share for a total of 600-700 million for both companies? Will that price work for a venture capital? Any thoughts? This legal drama has been dragging way too long.
okay, I read the 11/25 filing. Thank you for the clarification. The o/s is indeed 219 million and change. The question now becomes when and under what circumstances all those 250 million were issued? There was no announcement between 9/12 and now. It was only 42 million o/s on 9/12/14. Does anyone have a problem with that? I sure do. This was a massive dilution beyond belief, not to mention in the past summer 1 for 50 reverse split twice.
291 million shares? Where did you get that? Its 9/12/14 sec filing lists 42 million o/s. Since then, there has been no massive issurance announced. Did you make it up? Please show your source.
The single shot of the drug regardless what dosage was shown incapable to achieve f. cure, so they are going to try multiple shots at a high dosage. Is it going to arrive at a functional cure? Is it going to be safe? No one knows. Uncertainties. We are back to square one, plus the credibility issue. 5 dollar is the fair value, the market says. Any more missteps, it will go down further. Better sell, and buy back later if things change. just my opinion.
back in Feb, a little speculation pushed the stock to over 5 bucks. Now, a big deal in hand, the price can't hold on to 3 dollars. This is manupilation at its finest. But, folks, make no mistake about it that the drug works, and the price will double if not triple in a few months. It can only go up from here. You can bank on it!
What is a surprise is what it says. Below is what the company said about the top line trial results of the oral drug back in 2011
":Québec City, Canada, August 30, 2011 - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD). The results show that AEZS-130 reached its primary endpoint demonstrating 90% area-under-the-curve (AUC) of the Receiver Operating Characteristic (ROC) curve, which determines the level of specificity and sensitivity of the product. The Company is currently proceeding with further detailed analyses of the data and preparing for a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) in the upcoming months, which would be followed by the filing of a NDA for the registration of AEZS-130 in the United States.
The parameters of the study, as defined below under Study Design, were achieved as agreed to with FDA under our Special Protocol Assessment (SPA). Importantly, the primary efficacy parameters show that the study achieved both specificity and sensitivity at a level of 90% or greater. In addition, 8 of the 10 newly enrolled AGHD patients were correctly classified by a pre-specified peak GH threshold level. The use of AEZS-130 was shown to be safe and well tolerated overall throughout the completion of this trial."
what happened here?
it is nothing worth you losing sleep over, because either way it won't make or break the company. If you pay attention to the trading of past few months, you should know it. There has been no runup prior. Any upswing was quickly smacked down where it had been. So, if there is panic selling tomorrow because of crl, buy anything below a dollar. If it jumps up, sell anything around 1.50. Just my opinion.
The adcom vote is not a gaurantee that FDA will follow suit, though most of the times it does. The big money won't commit until after a fact. That is the reason. If fda rejects on Nov. 3, you will see a huge spike on lpcn in terms of both volumn and price, because that decision will effectively push lpcn to the top of the list of potential oral therapies. just my opinion.
The market seems to be waiting for FDA's decision on Rextoro on Nov 3. Any thoughts on how the desicion may impact lpcn-1201? A positive decision (unlikely)will push lpcn below 4 dollars, and a negative one will get it up to 7, and even 10?
While ibio has big potential from here onward, there are three big overhangs that can dampen the surge: 1) uncertainty of how big a contract they are going to get if they get it, 2) 23 million shares are slated to be sold to a venture capital fund (share purchase deal signed back in August) at a rate of 150k per day (probably already started), 3) inbp has 1.26 mill shares and is motivated to sell to pay down its debt.
In addition to all the above, insiders that have been holding their shares finally got a big break, don't you think they don't want to unload some and get themselves rewarded for hanging on all these years when the price had never gone over a buck?
I mention them just so we are not going to be carried away in the excitement. Last Thursday's rapid drop was a good example. So, proceed with caution. GL.
Their 10-Q/K said that they had 1.26 million ibio shares, and didn't sell any as of Sept, 8, 2014 when the report was filed, but probably sold some if not all of it in the recent price spike. They were obligated to sell when the price went below 88 cents to pay debt.
In most recent sec filing by ibio, ibio didn't mention those shares owned by inbp, but the two directors of inbp own a total of 11 mill shares of ibio, or over 8% each.
I want to add that google's influence might sway one or two judges, but it can't sway the whole court if vrng does have a legitimate issue here.
I would be very surprised if en banc should be rejected. The majority basically erred by overreaching on the basis of an issue repeatedly overrulled by the lower court judge. The case has to be heard by all the other judges in the court.
Your number is not right either. According to the company's second Q report, it has 2.6 mill s/o, so the market cap as of last friday stands at 14.5 mill, way undervalued. If you short, better cover now.
As of June 30, 2014, the comapny has 14 mill cash and 2.6 mill share outstanding. The market gives no value to its underlying business. Time to buy and accumulate. Just my opinion.